These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 27430905)
1. Enhanced efficacy of DNA vaccination against botulinum neurotoxin serotype A by co-administration of plasmids encoding DC-stimulating Flt3L and MIP-3α cytokines. Xu Q; Zhu YF; Wang HC; Gong ZW; Yu YZ Biologicals; 2016 Sep; 44(5):441-7. PubMed ID: 27430905 [TBL] [Abstract][Full Text] [Related]
2. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells. Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641 [TBL] [Abstract][Full Text] [Related]
3. Co-administration of antigen with chemokine MCP-3 or MDC/CCL22 enhances DNA vaccine potency. Xie X; Wang L; Yang W; Yu R; Li Q; Pang X Invest New Drugs; 2015 Aug; 33(4):810-5. PubMed ID: 25952465 [TBL] [Abstract][Full Text] [Related]
4. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Li N; Yu YZ; Yu WY; Sun ZW Immunopharmacol Immunotoxicol; 2011 Mar; 33(1):211-9. PubMed ID: 21284488 [TBL] [Abstract][Full Text] [Related]
5. Enhanced potency of replicon vaccine using one vector to simultaneously co-express antigen and interleukin-4 molecular adjuvant. Ma Y; An HJ; Wei XQ; Xu Q; Yu YZ; Sun ZW Hum Vaccin Immunother; 2013 Feb; 9(2):242-9. PubMed ID: 23291932 [TBL] [Abstract][Full Text] [Related]
6. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Yu YZ; Zhang SM; Sun ZW; Wang S; Yu WY Vaccine; 2007 Dec; 25(52):8843-50. PubMed ID: 18022294 [TBL] [Abstract][Full Text] [Related]
7. Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences. Yu YZ; Li N; Wang WB; Wang S; Ma Y; Yu WY; Sun ZW Vaccine; 2010 Nov; 28(47):7529-35. PubMed ID: 20854897 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-tumor effect of plasmid DNA-carrying MUC1 by the adjuvanticity of FLT3L in mouse model. Gao FS; Zhan YT; Wang XD; Zhang C Immunopharmacol Immunotoxicol; 2018 Aug; 40(4):353-357. PubMed ID: 30111221 [TBL] [Abstract][Full Text] [Related]
9. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Yu Y; Yu J; Li N; Wang S; Yu W; Sun Z Vaccine; 2009 Oct; 27(44):6148-53. PubMed ID: 19712769 [TBL] [Abstract][Full Text] [Related]
10. Binding activity and immunogenic characterization of recombinant C-terminal quarter and half of the heavy chain of botulinum neurotoxin serotype A. Yu YZ; Ma Y; Chen YX; Gong ZW; Wang S; Yu WY; Sun ZW Hum Vaccin; 2011 Oct; 7(10):1090-5. PubMed ID: 21941093 [TBL] [Abstract][Full Text] [Related]
11. Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting. Yu YZ; Li N; Wang S; Yu WY; Sun ZW Immunopharmacol Immunotoxicol; 2009; 31(3):397-404. PubMed ID: 19555205 [TBL] [Abstract][Full Text] [Related]
12. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine. Shih NY; Yang HY; Cheng HT; Hung YM; Yao YC; Zhu YH; Wu YC; Liu KJ J Immunother; 2009 May; 32(4):363-9. PubMed ID: 19342969 [TBL] [Abstract][Full Text] [Related]
13. Effects of MIP-1 alpha, MIP-3 alpha, and MIP-3 beta on the induction of HIV Gag-specific immune response with DNA vaccines. Song R; Liu S; Leong KW Mol Ther; 2007 May; 15(5):1007-15. PubMed ID: 17356539 [TBL] [Abstract][Full Text] [Related]
14. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Yu YZ; Sun ZW; Li N; Wang S; Wang RL; Yu WY Immunopharmacol Immunotoxicol; 2009 Jun; 31(2):261-6. PubMed ID: 18932057 [TBL] [Abstract][Full Text] [Related]
15. High-level expression of the Hcc domain of Clostridium botulinum neurotoxin serotype A in Escherichia coli and its immunogenicity as an antigen. Yu YZ; Sun ZW; Wang S; Yu WY Sheng Wu Gong Cheng Xue Bao; 2007 Sep; 23(5):812-7. PubMed ID: 18051857 [TBL] [Abstract][Full Text] [Related]
16. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related]
17. Fusion of antigen to chemokine CCL20 or CXCL13 strategy to enhance DNA vaccine potency. Guo JH; Fan MW; Sun JH; Jia R Int Immunopharmacol; 2009 Jul; 9(7-8):925-30. PubMed ID: 19348967 [TBL] [Abstract][Full Text] [Related]
18. Effects of MIP-1α, MIP-3α, and MIP-3β on the Induction of HIV Gag-specific Immune Response with DNA Vaccines. Song R; Liu S; Leong KW Mol Ther; 2007 May; 15(5):1007-1015. PubMed ID: 28182892 [TBL] [Abstract][Full Text] [Related]
19. Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response. Parajuli P; Pisarev V; Sublet J; Steffel A; Varney M; Singh R; LaFace D; Talmadge JE Cancer Res; 2001 Nov; 61(22):8227-34. PubMed ID: 11719454 [TBL] [Abstract][Full Text] [Related]
20. Augmented humoral and cellular immune response of hepatitis B virus DNA vaccine by micro-needle vaccination using Flt3L as an adjuvant. Zhou Q; Wang F; Yang F; Wang Y; Zhang X; Sun S Vaccine; 2010 Feb; 28(5):1357-62. PubMed ID: 19932674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]